The Health Resources and Services Administration’s proposed rule that would establish an administrative dispute resolution process for the 340B Drug Pricing Program “is an important first step for 340B hospitals and clinics that have been overcharged for drugs purchased through the program,” but there are several areas in which the rule could be amended, AHA said today. Specifically, the AHA urged HRSA to develop a “fast-track process” to provide 340B hospitals and other covered entities access to 340B drug ceiling prices, which “would help ensure a level-playing field in the dispute resolution process,” AHA Executive Vice President Tom Nickels said in a comment letter on the proposed rule. Among other proposals, AHA also commented on the ADR panel composition and decisions; information requests; and claims initiation and consolidation.

Related News Articles

Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The Centers for Medicare…
Blog
AHA staff recently visited two rural hospitals to see and hear firsthand how leaders are engaging in innovative practices to increase accessibility and…
Headline
The Centers for Medicare…
Headline
Tax-exempt hospitals in the 340B drug savings program provided $56.1 billion in total benefits to their communities in 2016, the most recent year for which…
Headline
The Centers for Medicare…